Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience experienced strong financial performance, with increased net sales, gross margin, and net income. Analysts maintained a positive outlook with "Buy" ratings and increased price targets for NAGE stock. The company launched Tru Niagen® Beauty and expanded the availability of Niagen Plus products. The FDA's reversal on NMN introduced uncertainty but highlighted Niagen's differentiation and patent protection. Niagen Bioscience launched a $10 million share repurchase program. A buy signal was issued from a pivot bottom point, indicating a potential further rise in the stock.

Information explicitly detailing demand seasonality for Niagen Bioscience's products and services was not found. The company's focus on healthy aging products might suggest a relatively stable demand throughout the year rather than strong seasonal fluctuations.

Niagen Bioscience, Inc. (NAGE), formerly ChromaDex Corporation, is a bioscience company focused on developing healthy aging products. The company operates in the Healthcare sector, specifically in the Biotechnology and Personal Care Products industries. Its business is segmented into Consumer Products, Ingredients, and Analytical Reference Standards and Services. The company offers finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, with Tru Niagen® as its flagship product. Niagen Bioscience develops and commercializes proprietary ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen, supplying these as raw materials to manufacturers of consumer products. The company provides phytochemical reference standards and other research and development services. Niagen Bioscience is a global leader in NAD+ science and research, with Niagen® being a patented ingredient that has demonstrated superior efficacy in increasing NAD+ levels.

Niagen Bioscience distributes its Tru Niagen® products in the United States through its e-commerce platform, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners. As of August 2025, Niagen Plus products were available in over 800 wellness clinics across the U.S. The company also has an international presence through a license agreement with Haukeland University Hospital in Norway to develop and commercialize Niagen® as a potential pharmaceutical therapy for Parkinson's disease.

Niagen Bioscience maintains a strong brand reputation in the healthy aging and NAD+ science sectors. Niagen® was recognized for its excellence in longevity science, earning the 2024 NutraIngredients EU Healthy Ageing Ingredient of the Year award. The company positions itself as the global leader in NAD+ research and technology. The FDA's reversal on NMN served to highlight Niagen Bioscience's differentiation, patent protection, and the proven efficacy and safety of Niagen®.

Niagen Bioscience has 296 institutional owners and shareholders holding a total of 36,184,580 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Nestlé S.A. Major individual owners include Hoi Shuen Chau, Frank Jaksch, Ozan Pamir, and Carlos Lopez.